GelStat Corp GSAC
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
GelStat Corp is a consumer healthcare company operating in the US. It is engaged in the development and marketing of over-the-counter (OTC) and other non-prescription consumer healthcare products. The company's lead product is Gelstat Migraine, which is a patented OTC homeopathic drug for use as a first-line, acute treatment for migraine and migraine-like headaches. The Gelstat Migraine is developed to provide acute relief from headache pain as well as other symptoms associated with a migraine. The other products of the company include CHEWS 2 LOSE, which is a diet aide in the form of an all-natural appetite suppressant gum; All Natural Speed which targets specific quick-fix energy user groups; and GelStat Sleep, which provides relief from sleep disorders and their associated symptoms.